COMMUNITY CLINICAL RESEARCH, INC. RESEARCH STUDY
Researchers in Austin, Texas are studying an investigational medicine for adults diagnosed with Major Depressive Disorder — and enrollment is now open.
About the study
The TARIAN-1 study is a Phase 2 clinical research study evaluating an investigational once-daily oral capsule in adults who have been diagnosed with Major Depressive Disorder (MDD).
Researchers want to understand how the study medicine behaves in the body and how it compares with a placebo (an inactive capsule). This is a placebo-controlled study, meaning some participants will receive the investigational medicine and some will receive a placebo. Each participant has an equal chance of being assigned to any group.
The study is being conducted at a single research site in Austin, Texas and is overseen by an independent Institutional Review Board (IRB) to protect the rights, safety, and wellbeing of all participants. No one will be enrolled without their full informed consent. Participation is completely voluntary.
Quick facts
Study Location
In-person clinic visits at a single research site in Austin, Texas
Time Commitment
Approximately 8 clinic visits over about 4 months
Who Can Join
Adults aged 18–75 with a diagnosis of recurrent Major Depressive Disorder
Reimbursement
Participants will receive reimbursement for their time and travel
What to expect
- Attend approximately 8 clinic visits at the Austin, Texas research site over about 4 months
- Complete questionnaires about mood and wellbeing at visits
- Take part in brief cognitive assessments and have blood draws
- Have a physical examination and heart rhythm check (ECG) at scheduled visits
- Take the study medicine as a once-daily oral capsule at home each morning on an empty stomach (first dose taken at the clinic)
- Take part in one Day 3 phone contact with the study team
Who can participate
- Adults aged 18 to 75 years (inclusive) at the time of consent
- Diagnosis of recurrent Major Depressive Disorder (MDD) confirmed under DSM-5-TR criteria, with at least one prior depressive episode (separate from the current episode)
- Current depressive episode lasting at least 6 weeks before the screening visit
- Not currently taking antidepressant medication, OR willing to stop antidepressant medication before the study baseline visit under medical guidance
- Willing and able to attend approximately 8 clinic visits in Austin, Texas over about 4 months
- Have access to email, internet, and/or video call for study-related communication
Benefits & Compensation
Research like the TARIAN-1 study helps increase understanding of how investigational medicines behave in the body and compare with placebo in adults living with Major Depressive Disorder.
See If You QualifySee if you qualify
Answer a few short questions to find out if you may be eligible for the TARIAN-1 study.
FAQ